Abstract
The study through Monte Carlo simulation of β-lactam pharmacokinetic/pharmacodynamic target attainment and determination of subsequent serum concentrations of piperacillin-tazobactam administered through continuous infusion to children treated for fever and neutropenia shows that 400 mg/kg/day has the highest probability of target attainment against Pseudomonas aeurginosa in our oncology ward compared with the standard regimen of 300 mg/kg/day.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Anti-Bacterial Agents / administration & dosage*
-
Anti-Bacterial Agents / pharmacokinetics*
-
Anti-Bacterial Agents / pharmacology
-
Child
-
Female
-
Fever of Unknown Origin / complications
-
Fever of Unknown Origin / drug therapy*
-
Humans
-
Infusions, Intravenous / methods
-
Male
-
Neutropenia / drug therapy*
-
Penicillanic Acid / administration & dosage
-
Penicillanic Acid / analogs & derivatives*
-
Penicillanic Acid / pharmacokinetics
-
Penicillanic Acid / pharmacology
-
Piperacillin / administration & dosage
-
Piperacillin / pharmacokinetics
-
Piperacillin / pharmacology
-
Piperacillin, Tazobactam Drug Combination
-
Pseudomonas Infections / drug therapy*
-
Treatment Outcome
Substances
-
Anti-Bacterial Agents
-
Piperacillin, Tazobactam Drug Combination
-
Penicillanic Acid
-
Piperacillin